Neuroendocrine tumours: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PD-1 1
• BRAF 0
• TP53 1
• PD-L1 0
• DLL3 14
• PI3K 0
• CTLA-4 0
• mTOR 1
• STAT3 0
• AKT 0
• MEK 0
• MAPK 0
• VEGF 1
• RET 0
• ERK 0
• STING 0
• YAP 0
• PRAME 0
• CTNNB1 0
• NRAS 0
• BAP1 0
• PTEN 0
• ALK 0
• EGFR 1
• MYC 0
• CXCR4 0
• EZH2 0
• HIF-1 0
• HSP90 0
• JNK 0
• PARP 5
• PSMA 3
• TNF 0
• CD40 0
• CDK4/6 0
• GPX4 0
• NRF2 0
• VHL 3
• AMPK 0
• B7-H3 2
• COX-2 0
• KRAS 0
• PPAR 0
• CD47 1
• KIT 1
• RAS 0
• TERT 0
• BRCA2 0
• CDKN2A 0
• GLP-1 0
• HER2 1
• IGF1R 0
• IL-17 0
• LAG-3 0
• MET 0
• MMP-9 0
• RB1 1
• TIGIT 0
• TROP2 1
• AXL 0

EU-13 is a filter, not a ranking: it only narrows the list.

2 of 2+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Updated 22 Sept 2026

  “Closed due to slow accrual.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)

  NCT04086485· National Cancer Institute (NCI)· Source

• Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors

  NCT04538378· National Cancer Institute (NCI)· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 50
• Organoids 14
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 13
• Gene Expression Profiling 118
• Sequence Analysis, RNA 8
• Whole Genome Sequencing 10
• Exome Sequencing 13
• Proteomics 49
• Metabolomics 20
• Mass Spectrometry 4
• Flow Cytometry 55
• Immunohistochemistry 185
• Liquid Biopsy 9
• Circulating Tumor DNA 35
• Xenograft Model Antitumor Assays 117
• Positron-Emission Tomography 61
• Magnetic Resonance Imaging 199
• Machine Learning 53
• Deep Learning 53
• Cohort Studies 80
• Genome-Wide Association Study 12

• Capture and Isolation of Circulating Melanoma Cells Using Photoacoustic Flowmetry.

  Methods Mol Biol, Jan 2027

• Imaging and Analysis of Melanoma-Secreted Extracellular Vesicles in Tumor-Draining Lymph Nodes.

  Methods Mol Biol, Jan 2027

• A Flow Cytometric Assay for Investigating Melanoma Cell Adhesion to Lymphatic Endothelial Cells.

  Methods Mol Biol, Jan 2027

• A Fluorescence-Based Assay for Measuring Glucose Uptake in Living Melanoma Cells.

  Methods Mol Biol, Jan 2027

• Evaluating Melanoma Cell Migration/Invasion in Transwell Assays by Flow Cytometry.

  Methods Mol Biol, Jan 2027

• Anti-tumour activity of canine activated T-cells and cytokine-induced killer cells against canine malignant melanoma in vitro.

  Vet J, Jul 2026

• Collision Tumor of Merkel Cell Carcinoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Cytological and Flow Cytometric Diagnostic Pitfall.

  Diagn Cytopathol, Jul 2026

• LNP-Delivered CAR-mRNA Enables in Vivo CAR-Macrophage Production for TYRP1-Targeted Therapy of Choroidal Melanoma.

  Curr Eye Res, Apr 2026

• Immunological phenotype as a predictor for response after isolated limb perfusion for patients with melanoma in-transit metastasis.

  Eur J Surg Oncol, Jan 2026

• PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.

  Nat Commun, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.